Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.58 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | CCNC | P24863 | 2/20 | 0.35 |
| ▸ | CDK8 | P49336 | 2/20 | 0.35 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | KDM6B | O15054 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3812402 | 0.98 | TDP1 (0.59) | TDP1SIRT3GSK3BMAPK1PTPN1 | |
| Hydrochloric Acid SCHEMBL641566 | 0.96 | TDP1 (0.58) | TDP1SIRT3GSK3BMAPK1PTPN1 | |
| SCHEMBL1889779 | 0.84 | TDP1 (0.46) | TDP1SIRT3GSK3BPTPN1KDM4C | |
| SCHEMBL3817557 | 0.81 | TDP1 (0.61) | TDP1SIRT3MAPK1TYK2SMN1; SMN2 | |
| SCHEMBL4974313 | 0.80 | SIRT3 (0.59) | TDP1SIRT3GSK3BMAPK1TYK2 | |
| SCHEMBL10808104 | 0.79 | SIRT3 (0.58) | TDP1SIRT3MAPK1TYK2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3092651 | 0.79 | SIRT3 (0.58) | TDP1SIRT3GSK3BMAPK1TYK2 | |
| SCHEMBL3821293 | 0.79 | TDP1 (0.41) | TDP1SIRT3GSK3BPTPN1SMN1; SMN2 | |
| Bromide SCHEMBL6117676 | 0.78 | HPGDS (0.39) | TDP1SIRT3GSK3BPTPN1SMN1; SMN2 | |
| SCHEMBL3817310 | 0.77 | SIRT3 (0.56) | TDP1SIRT3KDM4CSMYD3KDM6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2885306-B1 | IMIDAZO[2,1]THIAZOL-3-ONE DERIVATIVES USEFUL AS DIAGNOSTIC AGENTS FOR ALZHEIMER'S DISEASE | HOFFMANN LA ROCHE (CH) | 2016-06-01 | — | — | EP | disclosed |
| EP-2885306-A1 | IMIDAZO[2,1]THIAZOL-3-ONE DERIVATIVES USEFUL AS DIAGNOSTIC AGENTS FOR ALZHEIMER'S DISEASE | F. Hoffmann-La Roche AG (CH) | 2015-06-24 | — | — | EP | disclosed |
| US-20150157739-A1 | Imidazo[2,1]thiazol-3-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-06-11 | — | — | US | disclosed |
| WO-2014026881-A1 | IMIDAZO[2,1]THIAZOL-3-ONE DERIVATIVES USEFUL AS DIAGNOSTIC AGENTS FOR ALZHEIMER'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-20 | — | — | WO | disclosed |
| EP-1480976-B1 | THIAZOLE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-09-19 | — | — | EP | disclosed |
| US-7253197-B2 | Aminothiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1539722-A1 | THIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-15 | — | — | EP | disclosed |
| EP-1480976-A1 | THIAZOLE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-12-01 | — | — | EP | disclosed |
| EP-1438046-A4 | THIAZOLE BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CELL PROLIFERATION, AND METHODS FOR THEIR USE | AGOURON PHARMA (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1438046-A2 | THIAZOLE BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CELL PROLIFERATION, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2004-07-21 | — | — | EP | disclosed |
| US-6720346-B2 | (4-AMINOTHIAZOL-2-YLAMINO)-BENZAMIDE COMPOUNDS; PROTEIN KINASE INHIBITORS; CANCER; AUTOIMMUNE, VIRAL, FUNGAL, NEURODEGENERATIVE, AND CARDIOVASCULAR DISORDERS | AGOURON PHARMACEUTICALS, INC. | 2004-04-13 | — | — | US | disclosed |
| US-20040038990-A1 | Aminothiazole derivatives | HOFFMANN-LA ROCHE INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2004014884-A1 | THIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-02-19 | — | — | WO | disclosed |
| US-20030225147-A1 | Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use | AGOURON PHARMACEUTICALS INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003072577-A1 | THIAZOLE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003004467-A2 | THIAZOLE BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CELL PROLIFERATION, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225147-A1 | Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use | TK1, MKI67, CDKN1A | TDP1 1511/4885SIRT3 1276/4885GSK3B 498/4885 |
| US-20040038990-A1 | Aminothiazole derivatives | FABP4, GPR119, ABAT | TDP1 3210/4885SIRT3 639/4885GSK3B 2893/4885 |
| US-20150157739-A1 | Imidazo[2,1]thiazol-3-one derivatives | MAPT, SNCA, PARK7 | TDP1 412/4885SIRT3 3155/4885GSK3B 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.